Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of Becotatug Vedotin in platinum-resistant advanced cervical cancer
ChiCTR2600122667Phase 2Not yet recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in Cervical Cancer (CC), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Objective Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600122667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122667.